Clinical Trial Update: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC [Phase 2]

View source ↗

Summary

ClinicalTrials.gov update for a Phase 2 study evaluating efficacy, safety, pharmacokinetics, and dosimetry of Lu-177 PSMA-617 in Chinese adult males with progre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Pluvicto (lutetium-177 PSMA-617)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 2 | Status: ACTIVE_NOT_RECRUITING